Recurrent Prostate Cancer

Source: www.moreover.com --- 3 days ago
International Journal of Cancer, 09/10/08 World Journal of Urology, 09/04/08 ...

Source: www.ncbi.nlm.nih.gov --- 26 days ago
Related Articles Site-specific androgen receptor serine phosphorylation linked to epidermal growth factor-dependent growth of castration-Recurrent Prostate Cancer. J Biol Chem. 2008 Jul 25;283(30):20989-1001 Authors: Ponguta LA, Gregory CW, French FS, Wilson EM The androgen receptor (AR) is required for Prostate Cancer development and contributes to tumor progression after remission in response to androgen deprivation therapy. Epidermal growth factor (EGF) increases AR transcriptional activity at low levels of androgen in the CWR-R1 Prostate Cancer cell line derived from the castration-Recurrent CWR22 Prostate Cancer xenograft. Here we report that knockdown of AR decreases EGF stimulation of Prostate Cancer cell growth and demonstrate a mechanistic link between EGF and AR signaling. The EGF-induced increase in AR transcriptional activity is dependent on phosphorylation at mitogen-activated protein kinase consensus site Ser-515 in the AR NH(2)-terminal region and at protein kinase C consensus site Ser-578 in the AR DNA binding domain. Phosphorylation at these sites alters the nuclear-cytoplasmic shuttling of AR and AR interaction with the Ku-70/80 regulatory subunits of DNA-dependent protein kinase. Abolishing AR Ser-578 phosphorylation by introducing an S578A mutation eliminates the AR transcriptional response to EGF and increases both AR binding of Ku-70/80 and nuclear retention of AR in association with hyperphosphorylation of AR Ser ...

Source: www.prnewswire.com --- 24 days ago
...

Source: advancedprostatecancer.net --- 1 day ago
High Intensity Focused Ultrasound (HIFU) is a minimally invasive procedure that uses ultrasound energy to destroy cancerous tissue with focused sound waves. It has been used for a period of time in both Europe and Mexico as a primary Prostate Cancer treatment. Currently, in the United States there is a phase III trial [...] ...

Source: www.ncbi.nlm.nih.gov --- 18 days ago
Related Articles TMZ-BioShuttle - a reformulated Temozolomide. Int J Med Sci. 2008;5(5):273-284 Authors: Waldeck W, Wiessler M, Ehemann V, Pipkorn R, Spring H, Debus J, Didinger B, Mueller G, Langowski J, Braun K There is a large number of effective cytotoxic drugs whose side effect profile, efficacy, and long-term use in man are well understood and documented over decades of use in clinical routine e.g. in the treatment of Recurrent glioblastoma multiforme (GBM) and the hormone-refractory Prostate Cancer (HRPC). Both cancers are insensitive against most chemotherapeutic interventions; they have low response rates and poor prognoses. Some cytotoxic agents can be significantly improved by using modern technology of drug delivery or formulation. We succeeded to enhance the pharmacologic potency with simultaneous reduction of unwanted adverse reactions of the highly efficient chemotherapeutic temozolomide (TMZ) as an example. The TMZ connection to transporter molecules (TMZ-BioShuttle) resulted in a much higher pharmacological effect in glioma cell lines while using reduced doses. This permits the conclusion that a suitable chemistry could realize the ligation of pharmacologically active, but sensitive and highly unstable pharmaceutical ingredients without functional deprivation. The re-formulation of TMZ to TMZ-BioShuttle achieved a nearly 10-fold potential of the established pharmaceutic TMZ far beyond the treatment of brain tumors cel ...

Source: www.ncbi.nlm.nih.gov --- 3 days ago
Related Articles [Indications, techniques and outcomes of high-intensity focused ultrasound (HIFU) for the treatment of localized Prostate Cancer] Ann Urol (Paris). 2007 Oct;41(5):237-53 Authors: Poissonnier L, Murata FJ, Chapelon JY, Gelet A High-intensity focused ultrasound (HIFU) is a minimally invasive alternative for patients with localized Prostate Cancer, not suitable for radical prostatectomy because of a life expectancy less than 10 years or because of major co-morbidities precluding surgery. HIFU can be performed in patients with LUTS (associated TURP) or with a previous history of BPH surgery. HIFU is repeatable after the initial procedure if a Recurrent Cancer is diagnosed on control biopsies. Furthermore, this therapy is a viable option for patients with a local relapse after external beam radiation therapy: oncologic efficacy is conversely related to the initial Prostate Cancer stage before radiation therapy. PMID: 18265750 [PubMed - indexed for MEDLINE] ...

Source: forum.e2002.com --- 94 days ago
【nature】Recurrent gene fusions in Prostate Cancer 篇数：1 第1篇 【nature】Recurrent gene fusions in Prostate Cancer 作者：Chandan Kumar-Sinha1,2, Scott A. Tomlins1,2 & Arul M. Chinnaiyan 文章题目：Recurrent gene fusions in Prostate Cancer 杂志名全 ... ...

Source: prostatecancerinfolink.net --- 22 days ago
A new Phase III clinical trial is investigating the safety and efficacy of high intensity focused ultrasound (HIFU) for the treatment of locally Recurrent Prostate Cancer following failed external beam radiation therapy (EBRT). For more information about this trial, please see www.ProstateCancerRecurrentTrial.org or call 1-877-874-4389. Information about this trial does not appear to have been posted on the [...] ...

Source: cancertreatments.typepad.com --- 21 days ago
A study presented at the 2004 annual Clinical Congress of the American College of Surgeons wass the first to show that a Celebrex slowed the progression of Recurrent Prostate Cancer. The study was terminated early after information about the cardiovascular... ...

Source: www.medsci.org --- 20 days ago
There is a large number of effective cytotoxic drugs whose side effect profile, efficacy, and long-term use in man are well understood and documented over decades of use in clinical routine e.g. in the treatment of Recurrent glioblastoma multiforme (GBM) and the hormone-refractory Prostate Cancer (HRPC). Both cancers are insensitive against most chemotherapeutic interventions; they have low response rates and poor prognoses. Some cytotoxic agents can be significantly improved by using modern technology of drug delivery or formulation. We succeeded to enhance the pharmacologic potency with simultaneous reduction of unwanted adverse reactions of the highly efficient chemotherapeutic temozolomide (TMZ) as an example. The TMZ connection to transporter molecules (TMZ-BioShuttle) resulted in a much higher pharmacological effect in glioma cell lines while using reduced doses. This permits the conclusion that a suitable chemistry could realize the ligation of pharmacologically active, but sensitive and highly unstable pharmaceutical ingredients without functional deprivation. The re-formulation of TMZ to TMZ-BioShuttle achieved a nearly 10-fold potential of the established pharmaceutic TMZ far beyond the treatment of brain tumors cells and results in an attractive reformulated drug with enhanced therapeutic index. ...

Source: www.cancercompass.com --- 88 days ago
BALTIMORE -- Men whose tumors recur after Prostate Cancer surgery are three times more likely to survive their disease long term if they undergo radiotherapy within two years of the recurrence. Surprisingly, survival benefits were best in men whose new tumors were growing fastest, according to results of a "look-back" study of 635 men by Johns Hopkins Medical Institutions researchers reported June 18 in the Journal of the American Medical Association. Previous studies of radiation therapy for Recurrent Prostate Cancer found that it reduced disease progression, but this study demonstrates that it significantly prolongs survival, as well, according to Bruce J. Trock, Ph.D., associate professor of urology, epidemiology, oncology, and enviro... ...

Source: advancedprostatecancer.net --- 23 days ago
When we are diagnosed with Prostate Cancer, especially with Recurrent Prostate Cancer, we shoulder the emotional burden of telling our loved ones. This burden comes at the very same moment that we too are managing our own emotional response to the news. When diagnosed, we face an uphill emotional battle. At the exact time [...] ...

Source: advancedprostatecancer.net --- 34 days ago
Hair on a man’s head offers clues about versatility of a molecule central to Advanced Prostate Cancer. Once again, those of us fighting advanced and Recurrent Prostate Cancer are confronted with contradictory and confusing information. The usual first line treatment for advanced Prostate Cancer is hormone therapy (ADT). We all know that ADT is [...] ...

Source: advancedprostatecancer.net --- 1 day ago
A study which was funded by Cell Pathways Inc., developer of the drug Exisulind, suggest that Exisulind may delay disease progression in men with Recurrent Prostate Cancer according to Dr. Erik Goluboff, Assistant Professor of Urology at Columbia University College of Physicians & Surgeons, Director of Urology at The Allen Pavilion of New York-Presbyterian Hospital, [...] ...